Effect of Abdominal Wall Injections on Abdominal Pain

Last updated: November 7, 2023
Sponsor: Oregon Health and Science University
Overall Status: Active - Not Recruiting

Phase

4

Condition

Neuropathy

Colic

Peripheral Neuropathy

Treatment

Abdominal wall injections with lidocaine 2%

Clinical Study ID

NCT06121466
OregonHSUAWI
  • Ages 18-100
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Localized abdominal wall pain
  • Average daily pain (7-day recall) ≥ 3 on a scale of 0-10
  • Suspected abdominal wall etiology for abdominal pain
  • Positive Carnett's sign or pain near an incisional site
  • 18 years of age or older

Exclusion

Exclusion Criteria:

  • Suspected visceral etiology for the abdominal pain
  • Severe allergy to lidocaine
  • Unwillingness or inability to provide informed consent
  • Low probability of follow-up
  • Abdominal wall hernia noted at the point of pain
  • History of trigger point injections for abdominal pain
  • Bleeding disorder
  • Pregnancy, incarceration or decisionally impaired

Study Design

Total Participants: 45
Treatment Group(s): 1
Primary Treatment: Abdominal wall injections with lidocaine 2%
Phase: 4
Study Start date:
January 01, 2023
Estimated Completion Date:
January 31, 2025

Study Description

This is a prospective cohort study of outpatient adults with chronic abdominal wall pain who receive abdominal wall injections with lidocaine at an academic medical center. Thirty patients will be enrolled. A baseline assessment will include a medical history review and survey administration (Pain Catastrophizing Scale, Psychological Inflexibility in Pain Scale, Patient-Reported Outcomes Measurement Information System-29, Recurrent Abdominal Pain Intensity and Disability scale). Subjects will undergo Quantitative Sensory Testing to measure their pain tolerance and thresholds. The primary outcome to be measured is the change in abdominal wall pain at 1 week, 4 weeks and 12 weeks following the abdominal wall injection, with improvement defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale. Data analysis will consist of basic summary statistics to describe the mean, median, and standard deviation for demographic variables and clinical measures. A one-sample t-test or Wilcoxon test will be used to compare differences in continuous values between time points. Chi-square tests will be used to compare differences in categorical variables. An alpha of 0.05 will be used for all statistical tests. Univariate and multivariate logistic regression will be used to assess for factors associated with pain reduction.

Connect with a study center

  • OHSU

    Portland, Oregon 97239
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.